118996-64-8

Basic information

• Product Name: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile
• CAS NO: 118996-64-8
• Molecular Weight: 312.395
• Mol File: 118996-64-8.mol

Chemical Properties

• CAS DataBase Reference: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(118996-64-8)
• EPA Substance Registry System: 6-methylthio-4-morpholino-2-phenylpyrimidine-5-carbonitrile(118996-64-8)

Safety Data

• Hazardous Substances Data: 118996-64-8(Hazardous Substances Data)

Upstream product

• 3490-92-4 methyl 2-cyano-3,3-bis(methylsulfanyl)acrylate 
• 15908-64-2 3,4-dihydro-6-methymercapto-4-oxo-2-phenylpyrimidine-5-carbonitrile 
• 5147-80-8 [Bis(methylthio)methylene]malononitrile 
• 55-21-0 benzamide 
• 1670-14-0 benzamidine monohydrochloride 
• 110-91-8 morpholine 
• 118996-61-5 4-chloro-6-methylsulfanyl-2-phenyl-pyrimidine-5-carbonitrile 

Downstream Products

• 118996-78-4 5-amino-4-hydrazino-2-phenyl-7H-pyrazolo<3,4-d>pyrimidine 

Relevant articles and documents

New heterocyclic compounds

Provided herein are heterocyclic compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, wherein R1, R2, R3, R4 and R5 are as described herein. Further described herein in particular are heterocyclic compounds of the formula (I) for treating various diseases. and disorders by administering in a patient one or more TNF-α, Thromboxane synthase, 5-LOX, and PDE4 inhibitors. In particular described herein are methods for treating immunological diseases, inflammation, pain disorder, rheumatoid arthritis; osteoporosis; multiple myeloma; uveititis; acute and chronic myelogenous leukemia; ischemic heart disease; atherosclerosis; cancer; ischemic-induced cell damage; pancreatic beta cell destruction; osteoarthritis; rheumatoid spondylitis; gouty arthritis; inflammatory bowel disease; adult respiratory distress syndrome (ARDS); psoriasis; Crohn's disease; allergic rhinitis; ulcerative colitis; anaphylaxis; contact dermatitis; muscle degeneration; cachexia; asthma; bone resorption diseases; ischemia reperfusion injury; brain trauma; multiple sclerosis; sepsis; septic shock; toxic shock syndrome; fever, and myalgias due to infection and diseases mediated by HIV-1; HIV-2; HIV-3; cytomegalovirus (CMV); influenza; adenovirus; the herpes viruses (including HSV-1, HSV-2) and herpes zoster viruses in a mammal comprising administering an effective amount of a compound of formula (I).

Synthesis of Pyrimidine Derivatives by the Reaction of Ketene Dithioacetals with Amides

Reactions of methyl 2-cyano-3,3-bis(methylthio)acrylate (1a) with carboxamides 2a-g in the presence of sodium hydride in a mixture of benzene and N,N-dimethylacetamide took place displacement with the methylthio group to give the corresponding methyl 3-N-acylamino-2-cyano-3-(methylthio)acrylates 3a-g which were readily converted to the corresponding pyrimidine derivatives at reflux in methanol in good yields.Reactions of 2-cyano-3,3-bis(methylthio)acrylonitrile (1b) with the carboxamides 2a-f gave directly pyrimidine-5-carbonitrile derivatives 7a-f.Ketene dithioacetals 1a,b smoothly reacted with thioamide 2g or urea 2h,i to give the expected pyrimidine derivatives 9,10a,b.Polyfunctionalized pyrimidines, thus obtained, were also used for the synthesis of fused pyrimidine derivatives.